Market Overview:
The global selective Cox-2 inhibitors market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, such as rheumatoid arthritis, osteoarthritis, and spondylosis chronica ankylopoietica. In addition, the growing geriatric population is also contributing to the growth of this market. The global selective Cox-2 inhibitors market can be segmented on the basis of type into meloxicam, celecoxib, etoricoxib, imrecoxib, etodolac,, and parecoxib. On the basis of application,, it can be divided into rheumatoid arthritis,, osteoarthritis,, spondylosis chronica ankylopoietica,. and other applications. Geographically,. it can be segmented into North America,,,, Europe,,,, Asia Pacific,,,, Latin America,,,, Middle East & Africa (MEA), and Rest of World (RoW).
Product Definition:
Selective Cox-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that specifically blocks the action of cyclooxygenase-2 (Cox-2), an enzyme involved in inflammation. They are used to relieve pain and inflammation associated with conditions such as arthritis, menstrual cramps, and headaches.
Meloxicam:
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. It works by blocking the COX2 enzyme that causes pain, fever, and inflammation. The drug was first approved in Europe in 1996 for rheumatoid arthritis but it failed the FDA's approval because of too many side effects.
Celecoxib:
It is a non-steroidal anti-inflammatory drug (NSAID) and selective cyclooxygenase 2 inhibitor. It was developed by Bayer in the 1990s as an analgesic for pain management after being discovered to have greater than expected analgesic properties. In addition, it has been found to be more effective than indomethacin in treating acute upper respiratory tract infections, which includes common cold symptoms and flu.
Application Insights:
Rheumatoid arthritis dominated the market in 2017, owing to the increasing prevalence of this disease. According to a study published by the CDC in 2014, around 1.5 million people were diagnosed with RA and it is estimated that more than 2 million people were affected by this condition in the U.S., making it one of the most common diseases affecting older adults. Rheumatoid arthritis is also considered as an autoimmune disease since it involves a defect in immunity against joint tissues and organs caused due to damage done to immune cells patrolling joints tissues & organs during their migration through blood vessels towards muscles & tendons for attack on body¢â‚¬â„¢s own cells causing inflammation which eventually results into joint pain and swelling along with other associated symptoms such as loss of mobility ( stiffness) after injury or trauma, morning stiffness/pain/joints pain throughout day, redness or warmth at involved area etc.
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of a large number of key players and well-established healthcare infrastructure. The region is expected to maintain its dominance throughout the forecast period due to high consumer awareness and availability of effective treatment methods.
Asia Pacific is anticipated to be one of the fastest growing regions during the forecast period, mainly due to rising disposable income levels, improving economic conditions, expanding middle-class population base, increasing health consciousness among people aged 20 years & above and rising healthcare expenditure by governments. In addition, favorable regulatory policies are also expected favorably impact growth over coming years. For instance; in September 2016; China's State Food And Drug Administration (SFDA) approved Eisai Co., Ltd.'s application for marketing etoricoxib as a prescription drug for treating osteoarthritis related symptoms in patients over 60 years old with reduced risk of stomach ulcers and bleeding compared with other non-prescription drugs used for this purpose.
Growth Factors:
- Increasing incidence of chronic diseases such as cancer, arthritis, and heart disease is expected to drive the demand for selective Cox-2 inhibitors over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth as this population is more susceptible to chronic diseases.
- Rising awareness about the benefits of selective Cox-2 inhibitors over traditional NSAIDs is projected to propel market growth during the forecast period.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for players operating in this market over the next few years. 5) The increasing use of selective Cox-2 inhibitors in combination with other drugs for better treatment outcomes is also expected to fuel market growth during the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Selective Cox-2 Inhibitors Market Research Report
By Type
Meloxicam, Celecoxib, Etoricoxib, Imrecoxib, Etodolac, Parecoxib, Other
By Application
Rheumatoid Arthritis, Osteoarthritis, Spondylosis Chronica Ankylopoietica, Other
By Companies
Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla, Glenmark Pharmaceuticals, Teva, PuraCap Pharmaceutical, Almirall Limited, Lupin Pharmaceuticals, Aurobindo Pharma, Pfizer, Mylan, Takeda, Bayer, Novacap, Abbott, Geri-Care, Perrigo, Kopran, Merck, Hengrui pharmaceutical, Kelun Group, Qilu Pharmaceutical, Taro Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Selective Cox-2 Inhibitors Market Report Segments:
The global Selective Cox-2 Inhibitors market is segmented on the basis of:
Types
Meloxicam, Celecoxib, Etoricoxib, Imrecoxib, Etodolac, Parecoxib, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis, Osteoarthritis, Spondylosis Chronica Ankylopoietica, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer-Ingelheim
- TerSera Therapeutics
- Iroko Pharmaceuticals
- Apotex
- Yung Shin Pharmaceutical
- Breckenridge Pharmaceutical
- Meda Pharmaceuticals
- Cipla
- Glenmark Pharmaceuticals
- Teva
- PuraCap Pharmaceutical
- Almirall Limited
- Lupin Pharmaceuticals
- Aurobindo Pharma
- Pfizer
- Mylan
- Takeda
- Bayer
- Novacap
- Abbott
- Geri-Care
- Perrigo
- Kopran
- Merck
- Hengrui pharmaceutical
- Kelun Group
- Qilu Pharmaceutical
- Taro Pharmaceuticals
Highlights of The Selective Cox-2 Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Meloxicam
- Celecoxib
- Etoricoxib
- Imrecoxib
- Etodolac
- Parecoxib
- Other
- By Application:
- Rheumatoid Arthritis
- Osteoarthritis
- Spondylosis Chronica Ankylopoietica
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Selective Cox-2 Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Selective Cox-2 inhibitors are medications that block the activity of Cox-2 enzymes. These enzymes play a role in the process of inflammation and can lead to pain, swelling, and other symptoms. Selective Cox-2 inhibitors are often used to treat conditions like arthritis, cancer, and heart disease.
Some of the key players operating in the selective cox-2 inhibitors market are Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla, Glenmark Pharmaceuticals, Teva, PuraCap Pharmaceutical, Almirall Limited, Lupin Pharmaceuticals, Aurobindo Pharma, Pfizer, Mylan, Takeda, Bayer, Novacap, Abbott, Geri-Care, Perrigo, Kopran, Merck, Hengrui pharmaceutical, Kelun Group, Qilu Pharmaceutical, Taro Pharmaceuticals.
The selective cox-2 inhibitors market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Selective Cox-2 Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Selective Cox-2 Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Selective Cox-2 Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Selective Cox-2 Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Selective Cox-2 Inhibitors Market Size & Forecast, 2018-2028
4.5.1 Selective Cox-2 Inhibitors Market Size and Y-o-Y Growth
4.5.2 Selective Cox-2 Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Selective Cox-2 Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Selective Cox-2 Inhibitors Market Size Forecast by Type
5.2.1 Meloxicam
5.2.2 Celecoxib
5.2.3 Etoricoxib
5.2.4 Imrecoxib
5.2.5 Etodolac
5.2.6 Parecoxib
5.2.7 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Selective Cox-2 Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Selective Cox-2 Inhibitors Market Size Forecast by Applications
6.2.1 Rheumatoid Arthritis
6.2.2 Osteoarthritis
6.2.3 Spondylosis Chronica Ankylopoietica
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Selective Cox-2 Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Selective Cox-2 Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Selective Cox-2 Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America Selective Cox-2 Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Selective Cox-2 Inhibitors Market Size Forecast by Type
9.6.1 Meloxicam
9.6.2 Celecoxib
9.6.3 Etoricoxib
9.6.4 Imrecoxib
9.6.5 Etodolac
9.6.6 Parecoxib
9.6.7 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Selective Cox-2 Inhibitors Market Size Forecast by Applications
9.10.1 Rheumatoid Arthritis
9.10.2 Osteoarthritis
9.10.3 Spondylosis Chronica Ankylopoietica
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Selective Cox-2 Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe Selective Cox-2 Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Selective Cox-2 Inhibitors Market Size Forecast by Type
10.6.1 Meloxicam
10.6.2 Celecoxib
10.6.3 Etoricoxib
10.6.4 Imrecoxib
10.6.5 Etodolac
10.6.6 Parecoxib
10.6.7 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Selective Cox-2 Inhibitors Market Size Forecast by Applications
10.10.1 Rheumatoid Arthritis
10.10.2 Osteoarthritis
10.10.3 Spondylosis Chronica Ankylopoietica
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Selective Cox-2 Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Type
11.6.1 Meloxicam
11.6.2 Celecoxib
11.6.3 Etoricoxib
11.6.4 Imrecoxib
11.6.5 Etodolac
11.6.6 Parecoxib
11.6.7 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Applications
11.10.1 Rheumatoid Arthritis
11.10.2 Osteoarthritis
11.10.3 Spondylosis Chronica Ankylopoietica
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Selective Cox-2 Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America Selective Cox-2 Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Selective Cox-2 Inhibitors Market Size Forecast by Type
12.6.1 Meloxicam
12.6.2 Celecoxib
12.6.3 Etoricoxib
12.6.4 Imrecoxib
12.6.5 Etodolac
12.6.6 Parecoxib
12.6.7 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Selective Cox-2 Inhibitors Market Size Forecast by Applications
12.10.1 Rheumatoid Arthritis
12.10.2 Osteoarthritis
12.10.3 Spondylosis Chronica Ankylopoietica
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Selective Cox-2 Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Selective Cox-2 Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Selective Cox-2 Inhibitors Market Size Forecast by Type
13.6.1 Meloxicam
13.6.2 Celecoxib
13.6.3 Etoricoxib
13.6.4 Imrecoxib
13.6.5 Etodolac
13.6.6 Parecoxib
13.6.7 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Selective Cox-2 Inhibitors Market Size Forecast by Applications
13.10.1 Rheumatoid Arthritis
13.10.2 Osteoarthritis
13.10.3 Spondylosis Chronica Ankylopoietica
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Selective Cox-2 Inhibitors Market: Competitive Dashboard
14.2 Global Selective Cox-2 Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer-Ingelheim
14.3.2 TerSera Therapeutics
14.3.3 Iroko Pharmaceuticals
14.3.4 Apotex
14.3.5 Yung Shin Pharmaceutical
14.3.6 Breckenridge Pharmaceutical
14.3.7 Meda Pharmaceuticals
14.3.8 Cipla
14.3.9 Glenmark Pharmaceuticals
14.3.10 Teva
14.3.11 PuraCap Pharmaceutical
14.3.12 Almirall Limited
14.3.13 Lupin Pharmaceuticals
14.3.14 Aurobindo Pharma
14.3.15 Pfizer
14.3.16 Mylan
14.3.17 Takeda
14.3.18 Bayer
14.3.19 Novacap
14.3.20 Abbott
14.3.21 Geri-Care
14.3.22 Perrigo
14.3.23 Kopran
14.3.24 Merck
14.3.25 Hengrui pharmaceutical
14.3.26 Kelun Group
14.3.27 Qilu Pharmaceutical
14.3.28 Taro Pharmaceuticals
